ITGB3 and COVID-19: Quantitative IHC analysis demonstrated that patients with COVID-19 had significantly higher mean intensities of CD163 (8.5 ± 2.20 vs. 26.3 ± 1.15, P =  < 0.0001) and CD61 (0.28 ± 0.04 vs. 10 ± 0.78, P =  < 0.0001) staining than those without (Fig. 3C,F).